South Korea's Hanmi Pharmaceutical (128940: KS) has entered into a strategic partnership with the privately-owned Chinese biotech Innovent Biologics to co-develop and commercialize a novel immuno-oncology candidate on a global basis.
The project will use the Pentambody platform developed by Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi.
The technology is described by the company as a “next generation bispecific antibody platform that allows the combination of two different targeting modules in a single therapeutic agent.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze